Home/Pipeline/Undisclosed Biologic 1

Undisclosed Biologic 1

Oncology

Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Active

Company

Microviable Therapeutics

About Microviable Therapeutics

Microviable Therapeutics is a private, preclinical-stage biotech focused on harnessing the microbiome to develop live biotherapeutic products (LBPs). The company's core assets are three biological drugs nearing clinical development, targeting oncology and infectious diseases with antibiotic resistance. Beyond its internal pipeline, Microviable offers a range of services including custom biotherapeutic development, microbiota analysis, and markets GutAlive®, an anaerobic microbiome collection kit designed for clinical and research applications. The company appears to be pre-revenue, building value through its platform and pipeline.

View full company profile

Therapeutic Areas

Oncology Infectious Diseases

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active